Literature DB >> 27094695

The Relationship Among the Level of Serum Amyloid A, High-Density Lipoprotein and Microalbuminuria in Patients With Familial Mediterranean Fever.

Ali Ugur Uslu1, Bahattin Aydin2, Ibrahim Serhat Icagasıoğlu3, Sevket Balta4, Köksal Deveci3, Filiz Alkan3, Gürsel Yıldız5, Ali Sahin6.   

Abstract

BACKGROUND: Serum amyloid A (SAA), which is produced in the liver, acts as an apoprotein of high-density lipoprotein (HDL) accumulation in extracellular matrix of tissues and organs. SAA elevations play a significant role in the development of amyloidosis. Microalbuminuria (MAU) is the early period of amyloidosis in patients with familial Mediterranean fever (FMF). We assessed the association between SAA as an important factor for the development of amyloidosis in patients with FMF and cytokines, HDL, and MAU.
METHODS: A total of 40 FMF patients diagnosed with Tel-Hashomer criteria and making regular follow-up visits at the tertiary referral center from 2012 to 2013 were included in this study, besides 40 age- and sex-matched individuals as controls.
RESULTS: Compared with controls, FMF patients had higher SAA (25.20 ± 45.78 vs. 1.68 ± 0.63 ng/ml; P = 0.002). Also, FMF patients had higher MAU than controls (23.20 ± 39.86 vs. 9.40 ± 5.32 mg/day; P = 0.036). HDL was significantly lower in the patient group than in controls (39.35 ± 10.45 vs. 47.82 ± 15.31 mg/dl; P = 0.023). Interleukin-1 beta (IL-1), IL-6, and tumor necrosis factor alpha (TNF-α) levels were higher in the FMF group than in controls (P < 0.0001, P = 0.009, P = 0.003, respectively).
CONCLUSIONS: Our results suggest that IL-1, IL-6, TNF-α, SAA, and HDL may serve as markers of subclinical inflammation in FMF patients. Due to increased plasma HDL levels, antiinflammatory and antioxidant effects may elevate in FMF patients.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  familial Mediterranean fever; high-density lipoprotein; inflammation; microalbuminuria; serum amyloid A

Mesh:

Substances:

Year:  2016        PMID: 27094695      PMCID: PMC6807140          DOI: 10.1002/jcla.21971

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  32 in total

1.  Predictors of AA amyloidosis in familial Mediterranean fever.

Authors:  Nikolay A Mukhin; Lidiya V Kozlovskaya; Marina V Bogdanova; Vilen V Rameev; Sergey V Moiseev; Armine Kh Simonyan
Journal:  Rheumatol Int       Date:  2015-01-14       Impact factor: 2.631

2.  Not all inflammatory markers are linked to kidney function: results from a population-based study.

Authors:  Menno Pruijm; Belén Ponte; Peter Vollenweider; Vincent Mooser; Fred Paccaud; Gérard Waeber; Pedro Marques-Vidal; Michel Burnier; Murielle Bochud
Journal:  Am J Nephrol       Date:  2012-03-06       Impact factor: 3.754

Review 3.  Immune functions of serum amyloid A.

Authors:  Kari K Eklund; K Niemi; P T Kovanen
Journal:  Crit Rev Immunol       Date:  2012       Impact factor: 2.214

4.  Do neutrophil gelatinase-associated lipocalin and interleukin-18 predict renal dysfunction in patients with familial Mediterranean fever and amyloidosis?

Authors:  Köksal Deveci; Serdal Korkmaz; Soner Senel; Hulya Deveci; Enver Sancakdar; Ali U Uslu; Abdulkadir Deniz; Filiz Alkan; Mehmet M Seker; Mehmet Sencan
Journal:  Ren Fail       Date:  2013-12-09       Impact factor: 2.606

5.  Cystatin C in serum as an early marker of renal involvement in Familial Mediterranean Fever patients.

Authors:  K Deveci; A K Gokakin; S Senel; H Deveci; A U Uslu; E Sancakdar
Journal:  Eur Rev Med Pharmacol Sci       Date:  2013-01       Impact factor: 3.507

6.  Relation between microalbuminuria and gene mutations in familial Mediterranean fever.

Authors:  Müferet Ergüven; Can Emeksiz; Murat Deveci; Sare Gülfem Ozlü
Journal:  Turk J Pediatr       Date:  2008 Jul-Aug       Impact factor: 0.552

7.  A single testing of serum amyloid a levels as a tool for diagnosis and treatment dilemmas in familial Mediterranean fever.

Authors:  Yackov Berkun; Shai Padeh; Brian Reichman; Nurit Zaks; Einat Rabinovich; Merav Lidar; Bracha Shainberg; Avi Livneh
Journal:  Semin Arthritis Rheum       Date:  2007-05-23       Impact factor: 5.532

8.  C-reactive protein and microalbuminuria in a multi-ethnic Asian population.

Authors:  Charumathi Sabanayagam; Jeannette Lee; Anoop Shankar; Su Chi Lim; Tien Y Wong; E Shyong Tai
Journal:  Nephrol Dial Transplant       Date:  2009-11-13       Impact factor: 5.992

9.  Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations.

Authors:  H J Lachmann; B Sengül; T U Yavuzşen; D R Booth; S E Booth; A Bybee; J R Gallimore; M Soytürk; S Akar; M Tunca; P N Hawkins
Journal:  Rheumatology (Oxford)       Date:  2006-01-10       Impact factor: 7.580

Review 10.  Renal amyloidosis in children.

Authors:  Yelda Bilginer; Tekin Akpolat; Seza Ozen
Journal:  Pediatr Nephrol       Date:  2011-03-01       Impact factor: 3.714

View more
  3 in total

1.  Association of familial Mediterranean fever and epicardial adipose tissue: A systematic review and meta-analysis.

Authors:  Karam R Motawea; Omneya A Kandil; Joseph Varney; Merna Aboelenein; Nancy Ibrahim; Ahmed Shaheen; Lina T Khairy; Agyad Bakkour; Ali H H Muwaili; Dhuha H H Muwaili; Fatima A A Abdelmajid; Eman M S Ahmad; Mhd K Albuni; Elias Battikh; Bisher Sawaf; Sarya Swed; Safaa M A Ahmed; Dina M Awad; Jaffer Shah; Hani Aiash
Journal:  Health Sci Rep       Date:  2022-06-13

2.  Using urinary neutrophile gelatinase-associated lipocalin for prognosticate renal dysfunction in children with familial Mediterranean fever the study design: a pilot study.

Authors:  Sinem Can Oksay; Hasan Dursun; Sebnem Tekin Neijmann; Sami Hatipoglu
Journal:  Adv Rheumatol       Date:  2021-04-01

3.  Evaluation of Monocyte to High-Density Lipoprotein Cholesterol Ratio in the Presence and Severity of Metabolic Syndrome.

Authors:  Ali Ugur Uslu; Yahya Sekin; Gulten Tarhan; Nuray Canakcı; Mehmet Gunduz; Mustafa Karagulle
Journal:  Clin Appl Thromb Hemost       Date:  2017-12-06       Impact factor: 2.389

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.